Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

UCB 34714

Known as: UCB-34714, UCB34714 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Highly Cited
2008
Highly Cited
2008
Screening of 12 000 compounds for binding affinity to the synaptic vesicle protein 2A (SV2A), identified a high‐affinity… 
2008
2008
Background: Epilepsy is a neurological disorder with a worldwide prevalence estimated to be 0.5 – 1.0% of the population. Many… 
Review
2007
Review
2007
  • P. von Rosenstiel
  • Neurotherapeutics : the journal of the American…
  • 2007
  • Corpus ID: 43350812
Brivaracetam (UCB 34714) is chemically related to levetiracetam (LEV, Keppra). It possesses a binding affinity for the synaptic… 
Review
2006
Review
2006
  • M. Bialer
  • Expert opinion on investigational drugs
  • 2006
  • Corpus ID: 21166138
In the last decade, 10 new antiepileptic drugs (AEDs) have been introduced that offer appreciable advantages in terms of their… 
Review
2005
Review
2005
Brivaracetam (UCB-34714), an orally active, high-affinity synaptic vesicle protein 2A ligand, is being developed by UCB for the… 
Review
2004
Review
2004
The Seventh Eilat Conference on New Antiepileptic Drugs (AEDs) (EILAT VII) took place in Villasimius, Sardinia, Italy from the… 
Highly Cited
2004
Highly Cited
2004
(S)-alpha-ethyl-2-oxopyrrolidine acetamide 2 (levetiracetam, Keppra, UCB S.A.), a structural analogue of piracetam, has recently…